Tango Therapeutics has announced the first subject dosing in the open-label, multi-centre TNG456 Phase I/II trial.

Olezarsen is a promising treatment for severe hypertriglyceridemia, familial chylomicronemia syndrome and other dyslipidemia.

Satellos said that following the Phase I data, it will be advancing its DMD small molecule to a Phase II trial.

The US FDA has cleared Grifols' investigational new drug (IND) application to commence a Phase II trial of GRF312 Ophthalmic ...

Merck KGaA said that cohort A met the primary endpoint in the Phase II lupus trial but cohort B failed to meet its primary ...

AnnJi Pharmaceutical has reported encouraging outcomes from its randomised, placebo-controlled Phase I/IIa trial of AJ201.